Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PR-364
- Development stage
- Preclinical
- Lead developer
- Progenra
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
PR-364 is a selective, small-molecule activator of the E3 ubiquitin ligase Parkin (encoded by the PRKN/PARK2 gene), developed by Progenra. Discovered via high-throughput screening, PR-364 selectively promotes Parkin-dependent mitophagy and mitochondrial biogenesis without affecting other closely related E3 ligases. By enhancing the clearance of damaged mitochondria and boosting mitochondrial function, PR-364 has demonstrated therapeutic potential in preclinical models of acute pancreatitis, myocardial infarction (protecting against mortality and preventing progression to heart failure), and other conditions characterized by mitochondrial dysfunction.
02
Targets
PRKN (E3 ubiquitin-protein ligase parkin)
Beyond the preview
Go deeper on PR-364.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PR-364.